D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 82 Citations 28,309 400 World Ranking 8926 National Ranking 275

Overview

What is she best known for?

The fields of study she is best known for:

  • Cancer
  • Internal medicine
  • Surgery

Her primary areas of investigation include Internal medicine, Surgery, Oncology, Chemotherapy and Ovarian cancer. As a part of the same scientific study, she usually deals with the Internal medicine, concentrating on Gastroenterology and frequently concerns with Tolerability and Recurrent Ovarian Carcinoma. Her studies deal with areas such as Placebo, Urology, Radical surgery and Hazard ratio as well as Surgery.

Her Oncology research is multidisciplinary, relying on both Stage, Ovary, Clinical trial and Carcinoma. Her Chemotherapy research integrates issues from Ovarian carcinoma and Regimen. Her studies deal with areas such as Maintenance therapy and Phases of clinical research as well as Ovarian cancer.

Her most cited work include:

  • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. (890 citations)
  • Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (683 citations)
  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial (640 citations)

What are the main themes of her work throughout her whole career to date?

Internal medicine, Oncology, Ovarian cancer, Chemotherapy and Surgery are her primary areas of study. In her study, which falls under the umbrella issue of Internal medicine, Recurrent Ovarian Carcinoma is strongly linked to Placebo. Nicoletta Colombo has included themes like Phases of clinical research, Stage, Advanced ovarian cancer, Bevacizumab and Platinum sensitive in her Oncology study.

Her Ovarian cancer research focuses on Cancer research and how it relates to Ovarian carcinoma. Her Chemotherapy research incorporates themes from Regimen and Cervical cancer. Her research in Surgery intersects with topics in Gastroenterology, Debulking and Hazard ratio.

She most often published in these fields:

  • Internal medicine (66.46%)
  • Oncology (53.62%)
  • Ovarian cancer (37.68%)

What were the highlights of her more recent work (between 2018-2021)?

  • Internal medicine (66.46%)
  • Oncology (53.62%)
  • Chemotherapy (33.75%)

In recent papers she was focusing on the following fields of study:

Her primary scientific interests are in Internal medicine, Oncology, Chemotherapy, Ovarian cancer and Olaparib. Her study connects Placebo and Internal medicine. Her Oncology study combines topics in areas such as Bevacizumab, Carboplatin, Maintenance therapy and Germline.

Her study in Carboplatin is interdisciplinary in nature, drawing from both Randomized controlled trial, Paclitaxel and Atezolizumab. Her Chemotherapy research incorporates elements of Cervical cancer, Clinical endpoint and Radiology. Nicoletta Colombo studied Ovarian cancer and Stage that intersect with Serous fluid.

Between 2018 and 2021, her most popular works were:

  • Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. (234 citations)
  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (180 citations)
  • Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study (122 citations)

In her most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Chemotherapy

Nicoletta Colombo focuses on Internal medicine, Oncology, Ovarian cancer, Olaparib and Progression-free survival. Nicoletta Colombo focuses mostly in the field of Internal medicine, narrowing it down to topics relating to Placebo and, in certain cases, Hazard ratio. The various areas that Nicoletta Colombo examines in her Oncology study include Pembrolizumab, Newly diagnosed, Carcinoma, Bevacizumab and Double blind.

Her work deals with themes such as Gemcitabine, Gynecology and Case-control study, which intersect with Ovarian cancer. Her Progression-free survival study which covers Clinical trial that intersects with Cohort. Her studies in Clinical endpoint integrate themes in fields like Carboplatin and Gastroenterology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

MK Parmar;JA Ledermann;N Colombo;Bois A Du.
The Lancet (2003)

1426 Citations

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.

Nicoletta Colombo;Carien Creutzberg;Frederic Amant;Tjalling Bosse.
International Journal of Gynecological Cancer (2016)

1048 Citations

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski.
Lancet Oncology (2017)

982 Citations

THE EFFECT OF DEBULKING SURGERY AFTER INDUCTION CHEMOTHERAPY ON THE PROGNOSIS IN ADVANCED EPITHELIAL OVARIAN CANCER. GYNECOLOGICAL CANCER COOPERATIVE GROUP OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER

Maria E.L. van der Burg;Mat van Lent;Marc Buyse;Anna Kobierska.
The New England Journal of Medicine (1995)

948 Citations

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Kathleen Moore;Nicoletta Colombo;Giovanni Scambia;Byoung Gie Kim.
The New England Journal of Medicine (2018)

912 Citations

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

E A Eisenhauer;W W ten Bokkel Huinink;K D Swenerton;L Gianni.
Journal of Clinical Oncology (1994)

776 Citations

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian.
The Lancet (2017)

744 Citations

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

Michael A. Bookman;Mark F. Brady;William P. McGuire;Peter G. Harper.
Journal of Clinical Oncology (2009)

725 Citations

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

J.A. Ledermann;F.A. Raja;C. Fotopoulou;A. Gonzalez-Martin.
Annals of Oncology (2010)

666 Citations

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial

M. K B Parmar;M. Adams;M. Balestrino;K. Bertelsen.
The Lancet (2002)

634 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Nicoletta Colombo

Giovanni Scambia

Giovanni Scambia

Catholic University of the Sacred Heart

Publications: 209

Jalid Sehouli

Jalid Sehouli

Charité - University Medicine Berlin

Publications: 98

Ignace Vergote

Ignace Vergote

KU Leuven

Publications: 98

Robert L. Coleman

Robert L. Coleman

The University of Texas MD Anderson Cancer Center

Publications: 97

Amit M. Oza

Amit M. Oza

Princess Margaret Cancer Centre

Publications: 88

Gabriella Ferrandina

Gabriella Ferrandina

Catholic University of the Sacred Heart

Publications: 84

Bradley J. Monk

Bradley J. Monk

University of Arizona

Publications: 73

Ursula A. Matulonis

Ursula A. Matulonis

Harvard University

Publications: 72

Isabelle Ray-Coquard

Isabelle Ray-Coquard

Claude Bernard University Lyon 1

Publications: 71

Michael Friedlander

Michael Friedlander

University of New South Wales

Publications: 69

Jonathan A. Ledermann

Jonathan A. Ledermann

University College London

Publications: 68

Maurie Markman

Maurie Markman

The University of Texas MD Anderson Cancer Center

Publications: 67

Frédéric Amant

Frédéric Amant

Antoni van Leeuwenhoek Hospital

Publications: 65

Carol Aghajanian

Carol Aghajanian

Memorial Sloan Kettering Cancer Center

Publications: 65

Stan B. Kaye

Stan B. Kaye

Royal Marsden NHS Foundation Trust

Publications: 61

Dennis S. Chi

Dennis S. Chi

Memorial Sloan Kettering Cancer Center

Publications: 59

Trending Scientists

N. Vijaykrishnan

N. Vijaykrishnan

Pennsylvania State University

James T. C. Teng

James T. C. Teng

The University of Texas at Arlington

Flemming Frandsen

Flemming Frandsen

Technical University of Denmark

John M. Warman

John M. Warman

Delft University of Technology

Elena V. Pereloma

Elena V. Pereloma

University of Wollongong

Amanda D. Rodewald

Amanda D. Rodewald

Cornell University

Tony E. Hugli

Tony E. Hugli

Scripps Research Institute

David W. Martin

David W. Martin

University of Toronto

Michael G. Roth

Michael G. Roth

The University of Texas Southwestern Medical Center

Gordon A. McFeters

Gordon A. McFeters

Montana State University

Andrey Proshutinsky

Andrey Proshutinsky

Woods Hole Oceanographic Institution

Sylvie A. Quideau

Sylvie A. Quideau

University of Alberta

James J. Childress

James J. Childress

University of California, Santa Barbara

Pierre Ernst

Pierre Ernst

McGill University

Annalee Yassi

Annalee Yassi

University of British Columbia

Gerry Mooney

Gerry Mooney

The Open University

Something went wrong. Please try again later.